Sunshine Biopharma Inc (SBFMW) News

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 8-K - Current report

Form 8-K - Current report

Sunshine Biopharma Moves Principal Office to New York City

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a...

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a...

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

MONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company...

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company...

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company...

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

MONTREAL, April 05, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical...

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

MONTREAL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical...